GCAC Announces End-to-End SaaS Licensing for All Medical Cannabis Lifecycle Participants

Vancouver, British Columbia, Canada, October 29, 2020 – Global Cannabis Applications Corp. ("GCAC" or the "Company") (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading commercial licensor of proprietary Data and AI technologies to the medical cannabis industry, today announced the expansion of Citizen Green’s Software-as-a-Service (“SaaS”) commercial licensing to encompass the full medical cannabis product lifecycle. These new SaaS licenses expand upon the current Cultivator-SaaS license to now include SaaS for independent laboratories, medical cannabis vendors and authorized retailers.

The expanded Citizen Green SaaS licensing is comprised of:

- Laboratory SaaS: for independent labs to attest to medical cannabis test results;

- Distributor SaaS: for wholesale distributors to attest to their participation in the shipping, handling, forwarding and customs clearance of medical cannabis packages;

- Retailer SaaS: for vendors of medical cannabis to create Citizen Green product-lifecycle QR codes for their retail packaging, in order to generate efficacy data from consumers;

Fees are based on a SaaS monthly subscription starting at $199. Licensees pay-as-you-go for any extra company app users, a Know Your Customer “KYC” service, QR code generation and other software services. Detailed system pricing is provided per customer quote.

The Citizen Green platform is a blockchain enabled Seed to Sale to Seed technology solution that records every step in a medical cannabis products lifecycle, right up to consumption. The userfacing component of the Citizen Green family of technologies is the new Efixii-branded smartphone app. Efixii acquires medical cannabis lifecycle-data from SaaS licensees and then acquires efficacy-data directly from consumers. Efixii is free to download for consumers and has a built-in rewards service that complies with the Canadian Cannabis Act “Inducements” regulation.

“I chose the brand Efixii because I believe it reflects our commitment to creating better outcomes for medical cannabis consumers by truthfully acquiring product efficacy data” says Brad Moore, CEO of GCAC. “Medical cannabis lacks comprehensive clinical trials for a variety of reasons. Efixii draws efficacy responses into the public domain for cannabis cultivators, healthcare practitioners, and especially new consumers to understand the benefits of medical cannabis for them. An informed decision is so much better than a guess, and without trials or efficacy data, then we are all just guessing which cultivator’s product might work best for us and our families.”

GCAC has updated its CitizenGreen.io website with the latest SaaS licensing details and its sales team is ready to provide a pre-release of Efixii to interested medical cannabis lifecycle participants on a first come, first served basis. Efixii is configured with each SaaS licensee on a regional basis in order to meet local regulatory compliance requirements and is commencing in the Canadian and Israeli medical cannabis markets.